Close Menu

NEW YORK – OncoCyte said after the close of the market on Tuesday that its second quarter net loss rose year over year as it continues to advance its lung cancer liquid biopsy test, DetermaVu.

For the three months ended June 30, the Alameda, California-based diagnostic developer incurred a net loss of 5.4 million, or $.10 per share, compared to $4.5 million, or $.12 per share, in the year-ago period. Analysts on average had expected a loss per share of $.09.

OncoCyte did not report any revenues for the quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.